Endometriosis and Ovarian Cancer

Recent studies have provided much evidence to support the theory that endometriosis is actually a neoplasm and that affected cells can undergo malignant change. Women with endometriosis have a higher risk of certain types of ovarian cancer than the general female population [1]. Approximately 2.5 % of ovarian endometriosis turns malignant, but this may be an underestimation [2]. Studies have shown that Type 1 ovarian cancers such as clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) are associated with endometriosis [3]. Together, these carcinomas have been termed endometriosis-associated ovarian cancer (EAOC). The prevalence of endometriosis in ovarian cancer includes 39 % for clear cell carcinoma, 21 % for endometrioid carcinoma, and 3 % for serous and mucinous carcinoma [4]. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

Heidemann, L. N., Hartwell, D., Heidemann, C. H., & Jochumsen, K. M. (2014). The relation between endometriosis and ovarian cancer—A review. Acta Obstetricia et Gynecologica Scandinavica, 93(1), 20–31. Van Gorp, T., Amant, F., Neven, P., Vergote, I., & Moerman, P. (2004). Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Practice & Research. Clinical Obstetrics & Gynaecology, 18(2), 349–371. Kim, H. S., Kim, T. H., Chung, H. H., & Song, Y. S. (2014). Risk and prognosis of ovarian cancer in women with endometriosis: A meta-analysis. British Journal of Cancer, 110(7), 1878–1890. Yoshikawa, H., Jimbo, H., Okada, S., Matsumoto, K., Onda, T., Yasugi, T., et al. (2000). Prevalence of endometriosis in ovarian cancer. Gynecologic and Obstetric Investigation, 50(Suppl 1), 11–17. Sampson, J. A. (1927). Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. The American Journal of Pathology, 3(2): 93–110.143. Seli, E., Berkkanoglu, M., & Arici, A. (2003). Pathogenesis of endometriosis. Obstetrics and Gynecology Clinics of North America, 30(1), 41–61. Vercellini, P., Parazzini, F., Bolis, G., Carinelli, S., Dindelli, M., Vendola, N., et al. (1993). Endometriosis and ovarian cancer. American Journal of Obstetrics and Gynecology, 169(1), 181–182. Jimbo, H., Yoshikawa, H., Onda, T., Yasugi, T., Sakamoto, A., & Taketani, Y. (1997). Prevalence of ovarian endometriosis in epithelial ovarian cancer. International Journal of Gynaecology and Obstetrics, 59(3), 245–250. Fukunaga, M., Nomura, K., Ishikawa, E., & Ushigome, S. (1997). Ovarian atypical endometriosis: Its close association with malignant epithelial tumours. Histopathology, 30(3), 249–255. Liu, H., Leng, J., Lang, J., & Cui, Q. (2014). Clear cell carcinoma arising from abdominal wall endometriosis: A unique case with bladder and lymph node metastasis. World Journal of Surgical Oncology, 12, 51. Bischoff, F., & Simpson, J. L. (2004). Genetics of endometriosis: Heritability and candidate genes. Best Practice & Research. Clinical Obstetrics & Gynaecology, 18(2), 219–232. Tanase, Y., Furukawa, N., Kobayashi, H., & Matsumoto, T. (2013). Malignant transformation from endometriosis to atypical endometriosis and finally to endometrioid adenocarcinoma within 10 years. Case Reports in Oncology, 6(3), 480–484. Kobayashi, H., Kajiwara, H., Kanayama, S., Yamada, Y., Furukawa, N., Noguchi, T., et al. (2009). Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncology Reports, 22(2), 233–240. Gadducci, A., Lanfredini, N., & Tana, R. (2014). Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecological Endocrinology, 30(9), 612–617. Lin, K., Zhan, H., Ma, J., Xu, K., Wu, R., Zhou, C., et al. (2014). Increased steroid receptor RNA activator protein (SRAP) accompanied by decreased estrogen receptor-beta (ER-beta) levels during the malignant transformation of endometriosis associated ovarian clear cell carcinoma. Acta Histochemica, 116(5), 878–882. Kobayashi, H., Yamada, Y., Kanayama, S., Furukawa, N., Noguchi, T., Haruta, S., et al. (2009). The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 19(3), 471–479. Lyttle, B., Bernardi, L., & Pavone, M. E. (2014). Ovarian cancer in endometriosis: Clinical and molecular aspects. Minerva Ginecologica, 66(2), 155–164. Shigetomi, H., Higashiura, Y., Kajihara, H., & Kobayashi, H. (2012). A potential link of oxidative stress and cell cycle regulation for development of endometriosis. Gynecological Endocrinology, 28(11), 897–902. Nilbert, M., Pejovic, T., Mandahl, N., Iosif, S., Willen, H., & Mitelman, F. (1995). Monoclonal origin of endometriotic cysts. International Journal of Gynecological Cancer, 5(1), 61–63. Yamada, Y., Shigetomi, H., Onogi, A., Haruta, S., Kawaguchi, R., Yoshida, S., et al. (2011). Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 21(7), 1200–1207. Skliris, G. P., Munot, K., Bell, S. M., Carder, P. J., Lane, S., Horgan, K., et al. (2003). Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. The Journal of Pathology, 201(2), 213–220. Bossard, C., Busson, M., Vindrieux, D., Gaudin, F., Machelon, V., Brigitte, M., et al. (2012). Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One, 7(9), e44787. Ness, R. B. (2003). Endometriosis and ovarian cancer: Thoughts on shared pathophysiology. American Journal of Obstetrics and Gynecology, 189(1), 280–294. Crew, K. D., & Neugut, A. I. (2006). Aspirin and NSAIDs: Effects in breast and ovarian cancers. Current Opinion in Obstetrics and Gynecology, 18(1), 71–75. Vinatier, D., Dufour, P., & Oosterlynck, D. (1996). Immunological aspects of endometriosis. Human Reproduction Update, 2(5), 371–384. Gagnon, A., & Ye, B. (2008). Discovery and application of protein biomarkers for ovarian cancer. Current Opinion in Obstetrics and Gynecology, 20(1), 9–13. Hellstrom, I., & Hellstrom, K. E. (2008). SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Advances in Experimental Medicine and Biology, 622, 15–21. Moore, R. G., Brown, A. K., Miller, M. C., Skates, S., Allard, W. J., Verch, T., et al. (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology, 108(2), 402–408. Hellstrom, I., Raycraft, J., Hayden-Ledbetter, M., Ledbetter, J. A., Schummer, M., McIntosh, M., et al. (2003). The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research, 63(13), 3695–3700. Huhtinen, K., Suvitie, P., Hiissa, J., Junnila, J., Huvila, J., Kujari, H., et al. (2009). Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. British Journal of Cancer, 100(8), 1315–1319. Zhen, S., Bian, L. H., Chang, L. L., & Gao, X. (2014). Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. Molecular and Clinical Oncology, 2(4), 559–566. Burney, R. O., Hamilton, A. E., Aghajanova, L., Vo, K. C., Nezhat, C. N., Lessey, B. A., et al. (2009). MicroRNA expression profiling of eutopic secretory endometrium in women with versus without endometriosis. Molecular Human Reproduction, 15(10), 625–631. Suryawanshi, S., Vlad, A. M., Lin, H. M., Mantia-Smaldone, G., Laskey, R., Lee, M., et al. (2013). Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clinical Cancer Research, 19(5), 1213–1224. Kobayashi, H. (2009). Ovarian cancer in endometriosis: Epidemiology, natural history, and clinical diagnosis. International Journal of Clinical Oncology, 14(5), 378–382. Markman, M. (1997). The role of CA-125 in the management of ovarian cancer. The Oncologist, 2(1), 6–9. Havrilesky, L. J., Whitehead, C. M., Rubatt, J. M., Cheek, R. L., Groelke, J., He, Q., et al. (2008). Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecologic Oncology, 110(3), 374–382. Bazot, M., Darai, E., Nassar-Slaba, J., Lafont, C., & Thomassin-Naggara, I. (2008). Value of magnetic resonance imaging for the diagnosis of ovarian tumors: A review. Journal of Computer Assisted Tomography, 32(5), 712–723. Takeuchi, M., Matsuzaki, K., Uehara, H., & Nishitani, H. (2006). Malignant transformation of pelvic endometriosis: MR imaging findings and pathologic correlation. Radiographics, 26(2), 407–417. Author information Authors and Affiliations Corresponding author Rights and permissions Copyright information © 2015 The Author(s) About this chapter Cite this chapter Gupta, S. et al. (2015). Endometriosis and Ovarian Cancer. In: Endometriosis. SpringerBriefs in Reproductive Biology. Springer, Cham. https://doi.org/10.1007/978-3-319-18308-4_7 Download citation DOI: https://doi.org/10.1007/978-3-319-18308-4_7 Publisher Name: Springer, Cham Print ISBN: 978-3-319-18307-7 Online ISBN: 978-3-319-18308-4 eBook Packages: MedicineMedicine (R0)

- Ovarian Cancer - Malignant Transformation - Clear Cell Carcinoma - Human Epididymis Protein - Endometrioid Adenocarcinoma These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.